

Ibiayi Dagogo-Jack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7555085/publications.pdf>

Version: 2024-02-01

66
papers

5,457
citations

218592

26
h-index

143943

57
g-index

66
all docs

66
docs citations

66
times ranked

8002
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour heterogeneity and resistance to cancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 81-94.	12.5	2,149
2	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
3	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i> -Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206.	0.8	246
4	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in <i>ALK</i> -Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729.	7.7	228
5	Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377.	9.4	177
6	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i> -Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	158
7	SHP2 inhibition restores sensitivity in <i>ALK</i> -rearranged non-small-cell lung cancer resistant to <i>ALK</i> inhibitors. <i>Nature Medicine</i> , 2018, 24, 512-517.	15.2	155
8	<i>MET</i> Alterations Are a Recurring and Actionable Resistance Mechanism in <i>ALK</i> -Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	3.2	127
9	Treatment with Next-Generation <i>ALK</i> Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	3.2	122
10	Tracking the Evolution of Resistance to <i>ALK</i> Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
11	Impact of <i>BRAF</i> Mutation Class on Disease Characteristics and Clinical Outcomes in <i>BRAF</i> -mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 158-165.	3.2	81
12	Molecular Analysis of Plasma From Patients With <i>ROS1</i> -Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 816-824.	0.5	78
13	Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, <i>EGFR</i> -Mutant Lung Cancer Harboring De Novo <i>MET</i> Amplification. <i>Journal of Thoracic Oncology</i> , 2016, 11, e83-e85.	0.5	75
14	Clinicopathologic Characteristics of <i>BRG1</i> -Deficient NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 766-776.	0.5	68
15	Brigatinib in Patients With Alectinib-Refractory <i>ALK</i> -Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
16	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	3.2	62
17	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 255-264.	0.5	53
18	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in <i>ALK</i> -Positive NSCLC Refractory to Second-Generation <i>ALK</i> Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	0.5	53

#	ARTICLE	IF	CITATIONS
19	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506.	0.5	46
20	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017, 111, 61-64.	0.9	44
21	Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e226-e227.	0.5	43
22	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	2.3	36
23	Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. <i>Lung Cancer</i> , 2018, 122, 67-71.	0.9	35
24	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	0.5	35
25	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	5.8	35
26	Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?. <i>Oncologist</i> , 2016, 21, 662-663.	1.9	26
27	Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. <i>Journal of Thoracic Oncology</i> , 2019, 14, e226-e228.	0.5	24
28	Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1522-1528.	0.5	20
29	Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. <i>Lung Cancer</i> , 2019, 129, 80-84.	0.9	19
30	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	17
31	Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9611-9611.	0.8	17
32	Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer. <i>Cancer</i> , 2020, 126, 4473-4484.	2.0	14
33	Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. <i>Clinical Lung Cancer</i> , 2021, 22, 23-31.	1.1	14
34	Expanding the Roster of ROS1 Inhibitors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2595-2597.	0.8	12
35	Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, e174-e176.	0.5	11
36	A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. <i>Journal of Immunotherapy</i> , 2017, 40, 108-113.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precision Oncology, 2022, , .	1.5	10
38	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, e155-e157.	0.5	9
39	Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. Journal of Thoracic Oncology, 2019, 14, 835-843.	0.5	9
40	Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1441-1451.	1.3	9
41	Locally Recurrent Secretory Carcinoma of the Breast with <i>NTRK3</i> Gene Fusion. Oncologist, 2021, 26, 818-824.	1.9	8
42	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. JCO Precision Oncology, 2022, 6, e2100522.	1.5	8
43	The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Translational Lung Cancer Research, 2020, 9, 2557-2570.	1.3	6
44	Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.. Journal of Clinical Oncology, 2021, 39, TPS3152-TPS3152.	0.8	5
45	A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression.. Journal of Clinical Oncology, 2020, 38, 9595-9595.	0.8	5
46	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Annual Review of Cancer Biology, 2017, 1, 257-274.	2.3	4
47	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 619-629.	1.8	4
48	Inserting Ensartinib Into the Starting Lineup for <i>ALK</i> -Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench. JAMA Oncology, 2021, 7, 1615.	3.4	4
49	Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS3167-TPS3167.	0.8	4
50	Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer.. Journal of Clinical Oncology, 2021, 39, 243-243.	0.8	3
51	The Role of Liquid Biopsies in Lung Cancer Screening. Seminars in Roentgenology, 2017, 52, 185-187.	0.2	2
52	Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC. Journal of Thoracic Oncology, 2020, 15, 888-890.	0.5	2
53	Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.. Journal of Clinical Oncology, 2018, 36, 9093-9093.	0.8	2
54	Abstract 5172: B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma. Cancer Research, 2022, 82, 5172-5172.	0.4	2

#	ARTICLE	IF	CITATIONS
55	BRAF Mutation Class and Clinical Outcomesâ€™Response. Clinical Cancer Research, 2019, 25, 3189-3189.	3.2	1
56	GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. Neuro-Oncology, 2019, 21, vi111-vi111.	0.6	1
57	Retrospective analysis of activity of pembrolizumab (pembro) in melanoma patients (pts) with brain metastasis (BM).. Journal of Clinical Oncology, 2016, 34, 2071-2071.	0.8	1
58	Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2019, 37, 9069-9069.	0.8	1
59	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.. Journal of Clinical Oncology, 2021, 39, 8555-8555.	0.8	0
60	Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 8536-8536.	0.8	0
61	Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 12083-12083.	0.8	0
62	BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. Journal of Clinical Oncology, 2018, 36, 9045-9045.	0.8	0
63	Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.. Journal of Clinical Oncology, 2019, 37, 9068-9068.	0.8	0
64	Reply to the Letter to the Editor From Zhou etÂal. Journal of Thoracic Oncology, 2020, 15, e136-e137.	0.5	0
65	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-Oncology, 2021, 23, vi49-vi49.	0.6	0
66	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, e21024-e21024.	0.8	0